The Data
/
Stocks
/ ORMP
Equity · Healthcare
ORMP
NASDAQ
Oramed Pharmaceuticals Inc.
$4.75
−0.52% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 10, 2026
1D
1M
3M
1Y
5Y
All
Price · Chart
Our own end-of-day closes
36 sessions
The line runs $4.60 on 2 July through $4.75 on 10 September, on a scale from $3.5 to $5.5. Days the market did not trade hold the previous close, flat.
Interactive ORMP price chart by TradingView (requires JavaScript).
The chart above plots the price of ORMP over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 36 sessions over that window: $4.60 on 2 July 2026 through $4.75 on 10 September 2026.
Market cap
$197.6M
52-week range
$2.19 – $5.35
Avg volume
16.3K
Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 10, 2026
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals develops pharmaceutical products, including an oral insulin capsule and an oral COVID-19 vaccine. The company has conducted clinical trials for its oral insulin capsule, including a Phase 3 trial that did not meet its primary or secondary endpoints, leading to the discontinuation of clinical activities for type 2 diabetes. Oramed has analyzed trial data to identify responsive patient subpopulations and has submitted a new Phase 3 trial protocol to the FDA, while also evaluating its pipeline and potential strategic opportunities. The company has also conducted a Phase 1 clinical trial for its oral COVID-19 vaccine in South Africa.
Company
CEO
Nadav Kidron
Founded
2006
Headquarters
Jerusalem
Exchange
NasdaqCM
Sector
Healthcare
Class
Equity
Filings 5 sets
ORMP reported financials
SEC EDGAR XBRL
ORMP reported revenue of $2.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was $64.1M.
Figure
Reported
Period
Revenue
$2.0M
31 Dec 2025
fiscal year
Net income
$64.1M
31 Dec 2025
fiscal year
Diluted EPS
$1.50
31 Dec 2025
fiscal year
Total assets
$369.6M
30 Jun 2026
at period end
Total equity incl. minority interest
$317.5M
30 Jun 2026
at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
ORMP earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
$1.84
—
31 Mar 2026
Q1 2026
$0.91
—
31 Dec 2025
FY 2025
$1.50
$2M
30 Sep 2025
Q3 2025
$1.13
$2M
30 Jun 2025
Q2 2025
$0.31
$2M
31 Mar 2025
Q1 2025
$-0.19
$2M
31 Dec 2024
FY 2024
$-0.48
—
30 Sep 2024
Q3 2024
$-0.48
—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
4 of the 45 institutional funds we track reported a ORMP position for the quarter ended 30 Jun 2026 — a combined $1.7M; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
ORMP fails-to-deliver
SEC CNS data
On 28 Aug 2026, 802 shares of ORMP failed to deliver (about $4K) — the latest of 3 consecutive trading days with recorded fails.
Settlement date
Shares failed
Notional
% of shares out
28 Aug 2026
802
$4K
0.002%
27 Aug 2026
4,071
$22K
0.010%
26 Aug 2026
15,643
$82K
0.038%
21 Aug 2026
1,987
$10K
0.005%
Source: SEC fails-to-deliver (CNS) data
Congressional trades in ORMP
STOCK Act disclosures
The most recent congressional trade disclosed in ORMP is a purchase by Andrew R. Garbarino (house, NY), dated 23 Apr 2021.
Date
Member
Type
Amount
23 Apr 2021
filed 24 May 2021
Andrew R. Garbarino
house · Republican–NY
Purchase
$1K–$15K
Source: U.S. House of Representatives financial disclosures